Posts Tagged ‘fda’
No more excuses for pharma to put off using social media
This post was written by SmartBrief’s Elizabeth Collins. The pharmaceutical companies that say they are waiting for the Food and Drug Administration to issue new guidance on how to handle drug promotion through social media are just using the FDA’s guidance delay as an “out,” or an excuse, said Glenn Byrd, MedImmune’s director of regulatory [...]
Pharma, medial device leaders fret about social media’s lack of fact-checkability
“This is America. We’re talking about speech. Unless something’s really wrong, why not?” Panel experts voiced their support for allowing drug and health care companies to access the power of social networks during the Food and Drug Law Institute’s recent Advertising and Promotion Conference in Washington, D.C. These experts discussed how to communicate the message [...]
Drug companies, marketers need to monitor their brands on social media
This post is by Adam Gaub, lead editor, SmartBrief for Health Care Marketers. A new report issued today by marketing-technology company wool.labs analyzes seven years of social-media data and details the decline in consumers’ trust of GlaxoSmithKline’s diabetes drug Avandia, as well as in their doctors and the Food and Drug Administration. GSK has survived [...]
Today’s bonus tracks: Why social media is still a hard sell
Social media might be more popular than ever — but that doesn’t mean everyone is buying. Some people are still skeptical of the business utility of social media. B.L. Ochman argues that there are still three big factors scaring them off: culture clashes, consultants who make it sound harder than it really is and a [...]
